May 7 (Reuters) - Endo International PLC ENDP.O :
* ENDO REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE RELATING TO COVID-19 PANDEMIC
* Q1 ADJUSTED EARNINGS PER SHARE $0.95 FROM CONTINUING OPERATIONS
* Q1 EARNINGS PER SHARE $0.68 FROM CONTINUING OPERATIONS
* Q1 REVENUE $820 MILLION VERSUS REFINITIV IBES ESTIMATE OF $712.8 MILLION
* Q1 EARNINGS PER SHARE ESTIMATE $0.55 -- REFINITIV IBES DATA
* FULL-YEAR 2020 FINANCIAL GUIDANCE WITHDRAWN
* ENDO INTERNATIONAL - LAUNCH OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR TREATMENT OF CELLULITE IN BUTTOCKS MOVED TO FIRST-QUARTER 2021
* ANTICIPATES MODEST DELAYS IN PATIENT RECRUITMENT AND SITE SELECTION FOR NEW CLINICAL TRIALS AND ONGOING STUDIES
* ANTICIPATES A DECLINE IN GENERIC PHARMACEUTICALS REVENUES IN SECOND-QUARTER OF 2020 COMPARED TO FIRST-QUARTER OF 2020
* SEES Q2 TOTAL REVENUES TO DECLINE IN LOW 20'S PERCENTAGE RANGE COMPARED TO FIRST-QUARTER OF 2020
* SEES Q2 ADJUSTED GROSS MARGIN TO BE APPROXIMATELY 60 PERCENT OF REVENUES
* SEES Q2 ADJUSTED OPERATING EXPENSES TO BE APPROXIMATELY 25 PERCENT OF REVENUES